569 results on '"Grohé, Christian"'
Search Results
52. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
53. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
54. Lingua villosa nigra following initiation of antibiotic treatment for multidrug-resistent tuberculosis
55. Die Zeitenwende der chronisch fibrosierenden Lungengerüsterkrankung
56. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
57. SIADH: differential diagnosis and clinical management
58. Toll-Like Receptor-9 Polymorphisms in Sarcoidosis and Chronic Obstructive Pulmonary Disease
59. Pulmonary Arterial Hypertension in Patients with Sarcoidosis: The Pulsar Single Center Experience
60. Sex and Gender Differences in Pulmonary Diseases
61. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
62. Prognostic factors in non-small-cell lung cancer: insights from the German crisp registry
63. Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
64. Correlation of respiratory muscle function and cardiopulmonary exercise testing in post-acute COVID-19 syndrome
65. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
66. Adressen
67. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
68. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
69. Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
70. Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy.
71. Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.
72. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry
73. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln gemäß § 35a SGB V, veröffentlicht am 19. April 2022, Vorgangsnummer 2022-01-15-D-788, IQWiG Berichte Nr. 1329
74. Estrogens and the prevention of cardiac apoptosis
75. Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry.
76. Crosstalk between the Estrogen Receptor and the Insulin-Like Growth Factor (IGF-1) Receptor. Implications for Cardiac Disease
77. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET
78. Molecular biology of oncogenes and cardiovascular hypertrophy
79. Pulmonary Cylindromas in CYLD Cutaneous Syndrome: A Rare Differential Diagnosis of Pulmonary Adenoid Cystic Carcinoma
80. Differenzialdiagnose Lungenerkrankung – Wie sich das Häufige mit dem Seltenen erklären lässt!
81. Post-COVID und die Lunge
82. Cancer-Related Hyponatremia: Enhancing Recognition and Improving Management
83. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients
84. VEGF Gene Haplotypes Are Associated With Sarcoidosis
85. Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
86. Arthritiden und Lungenkavernen
87. Update 2021: Pulmonale Folgen nach COVID-19-Pneumonie
88. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk
89. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
90. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
91. Bilateral Pulmonary Cavitation as Predominant Phenotype in ANCA-Associated Disease
92. KEAP1 mutations in squamous cell lung cancer.
93. Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries.
94. Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
95. Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany
96. Lack of gelsolin promotes perpetuation of atrial fibrillation in the mouse heart
97. Toll-Like Receptor 2 Gene Polymorphisms Arg677Trp and Arg753Gln in Chronic Obstructive Pulmonary Disease
98. Use of Anticholinergic and Antifungal Pharmacotherapy for the Management of Bronchorrhea in a Patient With BRAF-Mutated Adenocarcinoma of the Lung
99. Sex-specific pathways in early cardiac response to pressure overload in mice
100. Vorbeugung chronischer Erkrankungen – heute wichtiger denn je
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.